Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Start price
21.08.23
/
50%
€762.50
Target price
21.08.24
€910.85
Performance (%)
19.66%
Price
08:00
€912.40
Summary
This prediction is currently active. The BUY prediction by Canaccord_Genuity_Gr currently has a performance of 19.66%. This prediction currently runs until 21.08.24. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.465% | 0.465% |
| iShares Core DAX® | -0.205% | 2.528% |
| iShares Nasdaq 100 | 1.613% | 4.733% |
| iShares Nikkei 225® | -0.740% | 0.396% |
| iShares S&P 500 | 0.267% | 2.720% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $992.00 price target on the stock, up previously from $720.00.
Ratings data for REGN provided by MarketBeat